Where to buy tesamorelin.

You can buy tesamorelin on prescription as Egrifta, or from a research-supply vendor as lyophilized lab powder. Those are the two live answers to where to buy tesamorelin, because the 503A compounding route narrowed sharply after 2023. Egrifta runs $3,500–$5,000 a month, while a research vial runs $80–$160.

Tesamorelin

Referenced in this guide

Batch-matched COAHPLC + mass specResearch use only

The Tesamorelin referenced throughout this article, supplied as a research compound with a certificate of analysis matched to the lot you receive — the check this site argues you should hold any supplier to.

Shop Tesamorelin

Where can you buy tesamorelin?

You can buy tesamorelin from a pharmacy on prescription as Egrifta, or from a research-supply vendor as Research Use Only powder. A 503A compounding pharmacy was a third route until the FDA narrowed it in 2023. Tesamorelin runs through three distinct US supply chains, and here is what each one gives you.

• Prescription Egrifta® / Egrifta SV®. The FDA-approved finished drug, made by Theratechnologies under cGMP. Dispensed by licensed pharmacies against a prescription. Labeled for HIV-associated lipodystrophy. Retail price: $3,500–$5,000 per month without insurance. Coverage outside the HIV indication is usually absent.
• 503A compounded tesamorelin. 503A is the section of federal law that lets compounding pharmacies prepare custom drugs for individual patients. The FDA's 2023 categorization decisions on bulk peptide substances narrowed this channel sharply. Most pharmacies that prepared tesamorelin no longer do.
• third-party tested tesamorelin (RUO). Lyophilized powder sold as a lab reference compound under Research Use Only labeling (21 CFR § 809.10(b)(9)). Not for human or animal use. 2026 pricing: $80–$220 per vial.

We focus on the third channel from here. If you have an HIV-lipodystrophy diagnosis and insurance coverage, the first channel is the right one. Talk to your physician rather than a vendor.

Which research-supply vendors to shortlist

Five vendors, ordered the way our supplier comparison orders them — on what each one will show you rather than what it claims — with every column pulled from the vendor's own storefront on 13 August 2026; there is no verified tesamorelin price anywhere in that set, so pricing is benchmarked on BPC-157 across the same vendors and no price column appears here.

Only the first two name their testing lab in their own site copy; on the other three you have to open the PDF and read the letterhead. Stock varies by compound, so confirm a vendor actually lists tesamorelin before you compare — what these columns describe is disclosure practice, and that is the part that travels across every compound a vendor sells. Disclosure: this site earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to. Every column above is a document you can open or a page you can load yourself.

We hold no verified CAS number for tesamorelin, so the identity check is the mass instead: the certificate should report an observed 5,196 Da for the hexenoyl-modified molecule, and a result near 5,135 Da is the bare 44-residue backbone rather than tesamorelin.

What is tesamorelin?

Tesamorelin is human GHRH(1-44) with one extra chemical group. The trans-3-hexenoyl modification on the N-terminus stops DPP-4 chewing up the peptide.

That stretches plasma half-life from about 7 minutes for native GHRH to roughly 26 minutes. We'd say that 19-minute extension is the entire reason tesamorelin works as a daily drug while unmodified analogs like sermorelin don't.

The mechanism is straightforward. Tesamorelin binds the GHRH receptor on pituitary somatotrophs, the cells that store and release growth hormone. The pituitary fires a GH pulse. The liver answers by making IGF-1, the main downstream mediator of GH's effects.

It's the same pathway native GHRH uses. The difference is that tesamorelin survives long enough to trigger a pulse before DPP-4 destroys it.

Pulsatility matters here. Recombinant GH produces a flat, non-pulsatile rise, and tissues respond less favorably to flat exposure than to discrete pulses. That's part of why tesamorelin produces metabolic effects at physiological GH levels rather than the supraphysiological exposures seen with recombinant GH.

The FDA approval rests on two large Phase III trials in HIV-associated lipodystrophy, which showed 15–18% visceral adipose tissue reduction at 26 weeks.

A 12-month double-blind trial in HIV-associated NAFLD has since produced secondary analyses on hepatic transcriptomics, plasma proteomics and immune-activation markers. A 2024 sub-analysis extends it to participants on integrase-inhibitor regimens.

How do you verify tesamorelin before you buy?

Four checks decide whether a tesamorelin vial is real. The mass-spec reading. Whether the CoA names the hexenoyl modification. The physical form. And the cold chain. The standard eight vendor criteria apply on top.

1. Mass-spec must show the modification

Tesamorelin's modified mass is 5,196 Da. The unmodified backbone is 5,135 Da. That 61 Da gap is small and unambiguous on any decent mass spectrometer.

If a CoA reports 5,135 Da, the hexenoyl coupling step failed and the vial holds plain GHRH(1-44). It binds about as well in a cell assay and carries sermorelin's 10-minute DPP-4-susceptible half-life. That isn't tesamorelin, and in our reading this one number is the most informative line on the whole CoA.

2. The CoA should name the hexenoyl modification

A real tesamorelin CoA names the modification. Some labs write "N-terminal trans-3-hexenoic acid modification." Others write "hexenoyl-GHRH(1-44)."

A CoA saying only "GHRH(1-44)" is describing either the unmodified peptide or one nobody characterized. Either way, our read is that it isn't what you're paying for.

3. Lyophilized, with no oral and no sublingual

Tesamorelin ships as lyophilized powder. That's the form approved as Egrifta and the form used in every published clinical trial. Pre-reconstituted liquid lasts weeks rather than years, and we've found no controlled validation for oral or sublingual formulations at all.

4. Cold chain still matters

The hexenoyl modification gives tesamorelin better storage stability than unmodified GHRH. The same DPP-4 resistance that extends plasma half-life also slows shelf degradation.

Lyophilized tesamorelin at −20°C is stable for years. Reconstituted and refrigerated at 2–8°C, it lasts 2–4 weeks, against the 1–2 weeks typical for unmodified GHRH analogs. A vendor shipping with no cold-chain documentation is cutting a corner the pharmacology doesn't justify.

What does tesamorelin cost in 2026?

Tesamorelin costs $80–$160 per 5 mg vial as a research compound, against $3,500–$5,000 a month for prescription Egrifta. At 44 residues it's one of the longer peptides in the GH-axis category, and every residue is another coupling step.

The hexenoyl modification adds specialized chemistry on top. That puts synthesis cost above shorter analogs like sermorelin at 29 residues and ipamorelin at 5, and well below tirzepatide. Here's the 2026 market.

• 5 mg vial: $80–$160 ($16–$32/mg). The most common third-party tested size.
• 10 mg vial: $120–$220 ($12–$22/mg). Better per-mg value.
• Multi-vial discounts: 10–25% off for 3- or 6-packs at most vendors.
• Reference point: prescription Egrifta runs $3,500–$5,000/month at US retail without insurance, because the labeled 2 mg daily dose adds up. The 20–30x gap buys FDA approval, cGMP oversight, finished drug-product formulation and a narrow labeled population. It isn't retail markup.

Below $60 per 5 mg vial, ask questions. The trans-3-hexenoyl coupling is one of the more failure-prone steps in the synthesis. Our read on a vendor selling tesamorelin at sermorelin prices is that they're shipping the unmodified backbone or a partial mixture. Above $35 per mg, you're paying retail markup rather than chemistry.

Is tesamorelin legal to buy?

Tesamorelin is legal to buy in the US as a Research Use Only compound, and legal to obtain as Egrifta on a prescription. Its regulatory picture is genuinely different from every other peptide in this category, because the molecule sits in five overlapping buckets at once.

• FDA-approved as Egrifta® (2010) and Egrifta SV® (2019). Theratechnologies holds the approval for "reduction of excess abdominal fat in HIV-infected patients with lipodystrophy." A real labeled indication backed by Phase III RCTs. Use outside the HIV-lipodystrophy indication does not have RCT-level validation.
• Sold as a Research Use Only compound. 21 CFR § 809.10(b)(9) covers RUO-labeled chemical substances. Selling tesamorelin for lab research is legal in the U.S. Selling it for human consumption isn't.
• Subject to 503A restrictions. The FDA's 2023 decisions on bulk peptide substances narrowed the 503A channel sharply. Most pharmacies that prepared tesamorelin for off-label clinical use no longer do.
• WADA-prohibited under S2, covering peptide hormones, growth factors and mimetics. Banned year-round. Detection methods are published, and accredited labs identify it routinely.
• EMA-withdrawn in 2020. Theratechnologies pulled Egrifta from the EU for commercial reasons, not safety. Health Canada approval remains.

Here's what matters for you. Research-labeled tesamorelin is legal to buy, sell and use in laboratory work. Giving it to a person or an animal outside the FDA approval framework is not.

What are the red flags when buying tesamorelin?

Seven things would stop us buying a tesamorelin vial. The first is decisive on its own, because 61 daltons separates the drug from a much cheaper peptide.

• Mass-spec at ~5,135 Da instead of ~5,196 Da. The hexenoyl coupling failed. You don't have tesamorelin.
• Vendors calling tesamorelin a "sermorelin alternative" without explaining the difference. Different molecules: 29 against 44 residues, unmodified against hexenoyl-modified, 10 minutes against 26. Conflating them is confusion or a sales pitch.
• Pre-reconstituted liquid without cold chain. Lyophilized survives shipping. Reconstituted at room temperature has a much shorter shelf life.
• Oral capsules, sublingual sprays, or transdermal patches. Zero validation in published research. Subcutaneous lyophilized is the form used in every trial.
• "Equivalent to Egrifta" with no mention of the research framework. Same molecule, different products, different oversight. A serious supplier makes that distinction for you.
• Clinical claims on the product page. "Tesamorelin reduces belly fat." "Tesamorelin for body recomposition." That's FDA enforcement territory.
• Internal-QC-only documentation. You want third-party ISO 17025 verification.

Tesamorelin

10 mg ≥99% pure Lyophilized

44-residue GHRH(1-44) with the N-terminal trans-3-hexenoyl modification — the same molecule as FDA-approved Egrifta. CoA confirms HPLC purity, mass-spec at ~5,196 Da (modification verified), and ISO 17025 third-party testing. The reference compound used across the cited Phase III and MGH HIV-NAFLD trial program.

Learn more

Frequently asked questions

Is third-party tested tesamorelin the same as Egrifta?

Chemically, yes. Both are the same 44-amino-acid GHRH(1-44) peptide with the N-terminal trans-3-hexenoic acid modification. What differs is the regulatory framing, the supply chain, the quality system and the dosage form.

Egrifta and Egrifta SV are FDA-approved finished drugs made under cGMP by Theratechnologies, dispensed by a licensed pharmacy on your prescription. Research tesamorelin is lyophilized powder under Research Use Only labeling, and not for human or animal use.

How much should third-party tested tesamorelin cost vs Egrifta?

You'll pay roughly $80–$160 per 5 mg vial and $120–$220 per 10 mg vial in 2026. Prescription Egrifta runs $3,500–$5,000/month at US retail without insurance, because the labeled dose is 2 mg daily. The 20–30x gap is approval, cGMP oversight, finished formulation and a narrow labeled population.

How is tesamorelin different from sermorelin?

Both are GHRH analogs hitting the same receptor on pituitary somatotrophs. The difference is half-life. Sermorelin is GHRH(1-29) with no stabilizing modification, and DPP-4 degrades it within minutes.

That's why sermorelin's clinical role is mostly diagnostic, testing pituitary GH capacity rather than treating anything. Tesamorelin is the full GHRH(1-44) sequence with the hexenoyl modification blocking DPP-4, which stretches half-life to about 26 minutes. That extension is why one has an FDA approval and the other doesn't.

Tesamorelin vs CJC-1295 — which one for research?

Both hit the same target, the GHRH receptor on pituitary somatotrophs. Tesamorelin is the full 44-residue GHRH(1-44) with the trans-3-hexenoyl modification, approved as Egrifta in 2010.

CJC-1295 is a shorter 30-residue modified GHRH(1-29), sometimes carrying a Drug Affinity Complex linker that binds albumin and stretches half-life to days. Its clinical development was discontinued, and it survives as a grey-market research peptide.

Same receptor, same mechanism, and only tesamorelin has the approval and the Phase III evidence. Our CJC-1295 vs tesamorelin comparison has the detail.

Is tesamorelin banned by WADA?

Yes. Tesamorelin is on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Banned year-round. Detection methods are published. WADA-accredited labs can identify it. The prohibition applies to athletic use, not lab research.

What should a tesamorelin CoA show?

HPLC purity ≥98% with the chromatogram. Mass-spec at the modified mass of about 5,196 Da, meaning the 44-residue backbone plus the trans-3-hexenoyl group. Karl Fischer water content 2–8%. Counterion content, usually trifluoroacetate or acetate.

The mass line has to confirm the modified peptide rather than the bare backbone. A mass missing the hexenoyl group means an incomplete synthesis. The lab should be ISO/IEC 17025 accredited and named on the report.